John Celebi - 19 Feb 2025 Form 4 Insider Report for Sensei Biotherapeutics, Inc. (SNSE)

Reporting relationship: PRESIDENT AND CEO, Director
Issuer ticker: SNSE
Reported as of: 19 Feb 2025
Net transaction value: -$2,646
SEC form: 4
Accepted by SEC: 26 Feb 2025, 18:45:30 UTC
Prior SEC filing: 14 Feb 2025
Source filing: View source filing
Reporting owner signature: /s/ Mark Ballantyne, Attorney-in-Fact

Key filing fact

John Celebi filed Form 4 for Sensei Biotherapeutics, Inc. (SNSE) on 26 Feb 2025.

Key facts

This page summarizes John Celebi's Form 4 filing for Sensei Biotherapeutics, Inc. (SNSE).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 26 Feb 2025, 18:45.

Change

Previous filing in this sequence was filed on 14 Feb 2025.
Current net transaction value: -$2,646.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SNSE transaction

Common Stock

Tax liability

Transaction value: $2,646
Shares: -5,558
Change %: -5%
Price: $0.4760
Shares after: 105,862
Date: 19 Feb 2025
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units.

Footnote F2

Includes an aggregate of 6,000 shares purchased by the Reporting Person since May 16, 2024 pursuant to the Issuer's 2021 Employee Stock Purchase Plan.